Last reviewed · How we verify

NCT04575753

Evaluating the Role of Pre-existing Resolvins in the Resolution of ICU Delirium

Withdrawn Last updated 30 March 2025
What this trial tests

trial testing Study group in Delirium. Withdrawn.

Timeline
7 October 2023
Primary endpoint
30 May 2024
30 June 2024

Quick facts

Lead sponsorUniversité Libre de Bruxelles
StatusWithdrawn
Study typeOBSERVATIONAL
Start date7 October 2023
Primary completion30 May 2024
Estimated completion30 June 2024
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Université Libre de Bruxelles — full company profile →

Who can join

18 and older, any sex, with Delirium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As patient management is improving, more and more ICU survivors are being confronted with cognitive dysfunction and this well after their hospital stay. In the ICU, delirium rates have been reported to be as high at 81%. Delirium is associated with patient and family stress, increased hospital costs, increased duration of stay, escalation of care and increased mortality and morbidity. The physiopathology of ICU cognitive impairment is complex and involves an inflammatory cascade Recently, the role of 'resolvins' derived from omega-3 fatty acids has been studied in the resolution of inflammation. Therefore, this hypothesis of this study is that ICU patients with higher serum levels of resolvins at ICU admission, ICU day 2 and day 5 will have a lesser degree of cognitive impairment on day 5 of ICU stay.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology.
    Dobrev D, Heijman J, Hiram R, Li N, et al · · 2023 · cited 207× · PMID 36109633 · DOI 10.1038/s41569-022-00759-w

Verify or expand the search:

Other trials of Study group

Trials testing the same drug.

Other recruiting trials for Delirium

Currently open trials in the same condition.

Other Université Libre de Bruxelles trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04575753.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing